News
SEEL
--
0.00%
--
Companies Smashing the Psychedelic Ceiling
/PRNewswire/ -- It's early on in a burgeoning market, but there is certainly reason to be optimistic about the future of psychedelic medicines as a promising treatment for a broad spectrum of diseases and conditions. In fact, some breakthroughs may be clos...
PR Newswire - PRF · 5d ago
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector.
Benzinga · 07/23 21:04
Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness
/PRNewswire/ -- The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illn...
PR Newswire - PRF · 07/21 12:45
Interest in "shroom stocks" rises as investors see potential of psychedelics as therapy
Moha El-Jaw/iStock via Getty Images "Magic mushrooms," LSD, and MDMA, once thought to be purely recreational drugs, are under investigation by many publicly traded companies as potential psychedelic treatments for
Seekingalpha · 07/17 20:00
10 Best Psychedelic Stocks to Buy Now
In this article, we discuss the 10 best psychedelic stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Psychedelic Stocks to Buy Now. Psychedelic treatments for mental health disorders like depression, a...
Insider Monkey · 07/14 16:57
Seelos Therapeutics to Participate in Two Investor Conferences in August
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will participate in two investor confere...
PR Newswire - PRF · 07/14 12:00
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha. In just a couple of years, psychedelics took the world of investing by storm.
Benzinga · 07/07 17:50
Seelos' Single Dose Of SLS-004 Shows Reduction In Parkinson's Associated mRNA, Protein Expression
Benzinga · 07/07 15:13
Thinking about buying stock in OncoSec Medical, Dare Bioscience, Jaguar Health, Americas Gold and Silver, or Seelos Therapeutics?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCS, DARE, JAGX, USAS, and SEEL.
PR Newswire - PRF · 07/07 12:30
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6)
Benzinga · 07/07 11:41
Seelos Therapeutics Announces In Vivo Data Demonstrating Down-Regulation Of SNCA mRNA And Protein Expression From Gene Therapy Study Of SLS-004 Utilizing CRISPR-dCas9 For Parkinson's Disease Pathology
Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced positive in vivo data
Benzinga · 07/07 11:01
Seelos Therapeutics Announces Positive In Vivo Data Demonstrating Down-Regulation of SNCA mRNA and Protein Expression from a Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 for Parkinson's Disease Pathology
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced positive in vivo data demonstrating down-regulation of SNCA...
PR Newswire · 07/07 11:00
Seelos Therapeutics Says Preliminary Data From Gene Therapy Study Shows Potential of Parkinson's Disease Drug Candidate
MT Newswires · 07/07 09:11
10 Psychedelic Startups Investors are Flocking To
In this article, we discuss the 10 psychedelic startups investors are flocking to. If you want to skip our detailed analysis of these startups, go directly to the 5 Psychedelic Startups Investors are Flocking To. One of the key developments in the psychede...
Insider Monkey · 07/06 20:47
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 07/06 20:31
Seelos Study of Racemic Ketamine for Acute Suicidal Patients Progresses to Dosing in Part Two
MT Newswires · 07/06 15:43
Seelos doses first patient in part 2 of SLS-002 major depressive disorder study
Seelos Therapeutics (SEEL) doses the first patient in part 2 of its Proof of Concept study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior ((ASIB)) in patients
Seekingalpha · 07/06 12:21
BRIEF-Seelos Therapeutics Doses First Patient In Part 2 Of A Registrational Study Of Sls-002 In Patients With Major Depressive Disorder
reuters.com · 07/06 12:05
Seelos Therapeutics Doses First Patient in Part 2 of a Registrational Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patient in Part 2, the ...
PR Newswire - PRF · 07/06 12:00
Why Seelos Therapeutics Is Moving Today
Seelos Therapeutics, Inc. (NASDAQ: SEEL) shares are trading higher after Guggenheim analyst Yatin Suneja initiated coverage on the stock with a Buy rating and announced an $8 price target.
Benzinga · 07/01 20:09
Webull provides a variety of real-time SEEL stock news. You can receive the latest news about Seelos Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SEEL
Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).